What is the kidney cancer?
kidney cell carcinoma (RCC), also referred to as hypernefroma, is the most common type of kidney cancer. This cancer affects cells lining small structures of a similar tube called proximal harmonized tubules, located in the kidney nephrines. The kidney cell cancer often does not represent symptoms until it reaches more advanced phases, when it can begin to show hematuria or blood in the urine, back pain, abdominal mass, weight loss, fever or high blood pressure.
The term renal concerns the kidney, the paired organ located in the rear or back of the abdomen that produces urine, cleans blood, regulates blood volume and pressure, and reabsorizes, among other things, useful proteins. Nephron is a functional unit in the kidneys responsible for regulating the water concentration in the body of blood filtration. The proximal intricate tube is one of the structures that make up nephron and are helpful in Reabsorup. sodium, sugars and water back into the bloodstream. Kidney cell cancer affects the epithelial tissue that leIt has a proximal tube and allows water and solutes such as sodium or sugars, to go back into the bloodstream.
The term carcinoma concerns malignant or gradually deteriorating cancer that affects epithelial cells. Epithelial tissue limits the surface of almost every organ in the body and provides important functions such as protection, secretion, diffusion and excretion. The whole epithelial tissue is separated from the inner tissue of the organ, which covers a layer of connective tissue called basement membrane . If the carcinoma has not progressed enough to damage the basement membrane or is considered malignant, it is called in situ or cis carcinoma. The kidney cancer, as well as other forms of cancer, can metastasize or spread, lymph or impact from the original location in the proximal tubule to other parts.
kidney cell carcinoma can be either hereditary or not hereditary. In both cases it changes withThe trructure of a particular gene in Chromosome 3 and then replicated to create a tumor. The tumor simply refers to swelling or matter caused by abnormal cell growth. Four hereditary syndromes associated with RCC are hereditary renal carcinoma (HRC), hereditary papillary renal carcinoma (HPRC), familial renal oncocytoma (FRO) and von hippel-lindau (VHL).
other than family history, risk factors that contribute to the probability of developing renal cell carcinoma, smoking; chronic dialysis; obesity; cadmium, benzene or trichlorethylene exposure; male sex; and progressing age. Like other cancer, patients with RCC have better success with the treatment earlier when they capture the disease. The chances of survival will fall drastically if the cancer metastasizes outside the kidneys. Doctors will probably diagnose patients suspected of having RCC with computer tomography (CT) scanning, magnetic resonance imaging (MRI) or ultrasound.
after diagnosis of patient with cancerRenal cells are decided on treatment based on how advanced cancer and patient's condition. Options include any combination or solo use of surgery, radiation therapy, hormonal therapy, chemotherapy or immunotherapy. If cancer is contained in the kidneys and the patient is healthy enough to withstand surgery, doctors can recommend surgical removal of the tumor in the procedure known as nephrectomy . This procedure may include a part or all renal removal and sometimes a excision of surrounding tissues and bladder.
If cancer is located in the kidneys, but the patient cannot withstand surgery, doctors may try to minimally invasive percutaneous therapy. During this procedure, the doctor uses CT scanning or other imaging mechanism to insert the data into the tumor and destroy it with heat or freezing. However, this method is not as effective as surgery in the removal of all cancer tissues.
In addition to complete chirIt is extremely difficult to cure kidney cancer. Radiation therapy is often not recommended because it has a low level of success. Hormonal therapy can reduce tumor growth. Chemotherapy is not usually successful, but the use of interleukin-2 (IL-2) has been approved for the treatment of kidney cancer and caused complete remission in a small percentage of patients. However, the IL-2 is very toxic, so the patient must be in good health to endure this treatment. Some medicines of kinase inhibitor, such as Sorafenib, have also been approved and showed the effectiveness of prolonging the life of patients with RCC